Literature DB >> 31803914

Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases.

Anders Jorsal1, Frederik Persson2, Jens Meldgaard Bruun3.   

Abstract

Entities:  

Year:  2020        PMID： 31803914     DOI： 10.1093/eurheartj/ehz777

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  3 in total

1.  Prognostic Value of the Residual SYNTAX Score on In-Hospital and Follow-Up Clinical Outcomes in ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions.

Authors:  Refik Emre Altekin; Ali Yasar Kilinc; Mehdi Onac; Orhan Cicekcibasi
Journal:  Cardiol Res Pract       Date:  2020-10-29       Impact factor: 1.866

Review 2.  Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.

Authors:  Guntram Schernthaner; Naim Shehadeh; Alexander S Ametov; Anna V Bazarova; Fahim Ebrahimi; Peter Fasching; Andrej Janež; Péter Kempler; Ilze Konrāde; Nebojša M Lalić; Boris Mankovsky; Emil Martinka; Dario Rahelić; Cristian Serafinceanu; Jan Škrha; Tsvetalina Tankova; Žydrūnė Visockienė
Journal:  Cardiovasc Diabetol       Date:  2020-10-23       Impact factor: 9.951

Review 3.  Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.

Authors:  Magdy Abdelhamid; Hossam Kandil; Mahmoud Hassanin; Sameh Shaheen; Mohamed Sobhy; Adel ElEtreby; Hosam Hasan-Ali; Hala Mahfouz; Gamila Nasr; Islam Shawky; Sameh Emil; Mohamed ElSetiha; Mohamed Hasssan; Yasser Sadek; Mohamed Abdelghany Karim; Ayman Asham; Mohamed Ghaleb; Ahmad Samir; Khaled Shokry
Journal:  ESC Heart Fail       Date:  2022-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.